Gsk Share Discussion Threads

[alibizzle] 12/2/2023 17:47

In the article it said cakifornia courts more sympathetic to claimsnts as more based on emotions than scientific evidence citing the Bayer 2019 case . So not good news for shareholders once again

[netcurtains] 12/2/2023 17:39

Article in todays Times says court case starts next week.

Its annoying that the claimants team know if they are going to throw in the towel and buy GSK before the public......

They are the only ones who know for sure what they are going to do.

[tradermichael] 11/2/2023 09:35

The answer is YES!

Also, several high value collaborations and joint ventures are in existence. Wave Life Sciences, CureVac, Isis Pharma, Arrowhead Pharmaceuticals are just a few.

[maxplus2] 10/2/2023 17:24

Thank you. Is,GSK doing any research in mRNA?

[alibizzle] 10/2/2023 15:28

I think so fallen due to nervous investors with upcoming litigation in Cali . If that goes well hopefully be a.recovery

[tradermichael] 10/2/2023 15:09

maxplus: So why did the share price have gone down


Probably due to Pfizer, BioNTech starting trial for first mRNA-based shingles vaccine which is seen as a threat to GSK's 'Shingrix'

[geckotheglorious] 10/2/2023 14:59

Pfizer, BioNTech start trial for first mRNA-based shingles vaccine

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) announced Friday the start of a Phase 1/2 trial for the companies' mRNA vaccine candidates against shingles, an infectious disease caused by the reactivation of chickenpox virus.

The companies said that the program combines Pfizer's (PFE) antigen technology with BioNTech's (BNTX) mRNA platform technology, which led to the first U.S.-approved COVID-19 vaccine in 2020.

The U.S.-based trial is designed to evaluate the safety, tolerability, and immunogenicity of mRNA-based shingles vaccines involving up to 900 healthy volunteers aged 50 – 69.

The companies have designed the mRNA technology to target the glycoprotein E ((gE)) on the surface of the varicella-zoster virus (VZV), which leads to chickenpox as a primary infection, usually during childhood.

A condition characterized by a painful localized rash, shingles affects millions of people globally each year, with its incidence and severity rising with age.

Pfizer (PFE) and BioNTech (BNTX) first announced a collaboration for an mRNA-based shingles vaccine in January 2022.

Merck (MRK) and GSK (GSK) dominate the global shingles vaccine market with their Zostavax and Shingrix vaccines, respectively.

[abdullla] 10/2/2023 14:56

Its gone down because of the unfinished litigation in the case of Zantac

[maxplus2] 10/2/2023 12:24

So why did the share price have gone down

[alphorn] 10/2/2023 10:59

Interesting to note a full approval after PI results. Unusual.

[tradermichael] 10/2/2023 10:53

GSK PLC said Friday that the U.S. Food and Drug Administration has given full approval for its Jemperli endometrial cancer treatment.

The pharmaceutical giant said approval was based on long-term outcomes from the Garnet Phase 1 trial, which showed an overall response rate of 45.4%.

Jemperli has been approved for the treatment of adult patients with mismatch repair-deficient recurrent or advanced endometrial cancer. In April 2021, the treatment received accelerated approval.

Jemperli was discovered by AnaptysBio Inc. and licensed to Tesaro Inc., now a part of GSK, under a collaboration and exclusive license agreement signed in March 2014.

[wsm812] 09/2/2023 11:31

The problem we may have is all of those investers who bought in around the mid 1700s may start selling, if they have leveraged down and meet a B.E.P, as having to hold a stock this long to see profit may be too tempting. The court cases are the injection of faith needed to properly boost the share price once again.

[netcurtains] 09/2/2023 11:26

So it was about 1700 before the court cases.
Any chance of getting back there if the results go our way?

[maxplus2] 09/2/2023 11:12

Ex Divi 23 Feb

[wsm812] 09/2/2023 10:35

Could see share price resitance between 1520 - 1560, previously lower levels from March 2022. 1600 awaits if cleared.

[tradermichael] 09/2/2023 09:45

They can take up to 2 years, however:

FDA and EMA have already concluded there is no evidence of a causal association between ranitidine therapy and the development of cancer. Substantial scientific evidence supports FDA/EMA conclusion.

"The overwhelming weight of the scientific evidence supports the conclusion that there is no increased cancer risk associated with the use of ranitidine. Suggestions to the contrary are therefore inconsistent with the science, and GSK will continue to vigorously defend itself against all claims alleging otherwise."

[alibizzle] 09/2/2023 09:30

I wonder how long these court cases take , days or weeks ? Hopefully positive outcome

[netcurtains] 09/2/2023 07:53

Thanks zho: That sounds quite encouraging.

[tradermichael] 09/2/2023 07:27

Its possible that GSK is benefitting from Pfizer's Covid 'reset' and subsequent downgrades.

[zho] 08/2/2023 14:31

>>Has that California court case started?>>

Among the state court cases naming GSK, a trial in California is currently scheduled to begin 13 February 2023 and a trial is currently scheduled to begin in Madison County, Illinois in February 2023.

[netcurtains] 08/2/2023 14:28

Has that California court case started? Is this what this is about?
If not, how near before we have a start date?
Thanks for any info.
Cheers Net.

[anhar] 08/2/2023 11:02

Consider this: today they are +10 on 1495 and some holders think this is a strong start. If the price was 149.5, then a rise of +1 wouldn't impress.

Who are the "some holders" TM? Only a few PIs may think mistakenly like that and they are irrelevant to the market in a share the size of GSK.

[alibizzle] 08/2/2023 10:52

£15 barrier broken ! Upwards and onwards or slow fizzle back to £14 . It's GSK , anything can happen !

[tradermichael] 08/2/2023 08:42

When the company split off the Healthcare operation, I wish they'd have also issued a 10 for 1 split to form new GSK.

Consider this: today they are +10 on 1495 and some holders think this is a strong start. If the price was 149.5, then a rise of +1 wouldn't impress.